RxDoctor Payments Data

Son Do, MD

Gastroenterology · Vancouver, WANPI 1285668822

Payments from drug & device makers

$5,414in general payments, 2019–2025

Across 120 payments — averaging $45.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$955
  • Takeda Pharmaceuticals U.S.A., Inc.$677
  • Johnson & Johnson$289
  • Ferring Pharmaceuticals Inc.$259
  • Intercept Pharmaceuticals, Inc.$229
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$76514%
  • Food & beverage$4,56184%
  • Education$882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,414 in reported general payments places this provider in the 80th percentile of 447 gastroenterology providers in Washington.

See all gastroenterology providers in Washington

Medicare billing

Part B allowed, 2024
$80,611
Medicare patients
334
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$420,627
ZenpepLipase/Protease/Amylase39$77,148
XifaxanRifaximin13$45,403
LinzessLinaclotide35$30,862
Omeprazole185$3,547
Budesonide DrBudesonide46$3,231
Mesalamine12$3,141
Lubiprostone21$2,999
Budesonide EcBudesonide15$2,917
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$2,005
Pantoprazole Sodium176$1,853
Ursodiol14$1,706
Balsalazide Disodium16$1,572
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl88$1,570
CholestyramineCholestyramine (With Sugar)15$1,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$289$420,62716 claims
Aimmune Therapeutics, Inc.Zenpep$150$77,14839 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$75$45,40313 claims
AbbVieLinzess$1,164$30,86235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 447 gastroenterology providers in Washington.

Other gastroenterology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →